| http://purl.uniprot.org/citations/25042253 | http://www.w3.org/1999/02/22-rdf-syntax-ns#type | http://purl.uniprot.org/core/Journal_Citation |
| http://purl.uniprot.org/citations/25042253 | http://www.w3.org/2000/01/rdf-schema#comment | "Optimization of AZD6482 (2), the first antiplatelet PI3Kβ inhibitor evaluated in man, focused on improving the pharmacokinetic profile to a level compatible with once daily oral dosing as well as achieving adequate selectivity towards PI3Kα to minimize the risk for insulin resistance. Structure-based design and optimization of DMPK properties resulted in (R)-16, a novel, orally bioavailable PI3Kβ inhibitor with potent in vivo anti-thrombotic effect with excellent separation to bleeding risk and insulin resistance."xsd:string |
| http://purl.uniprot.org/citations/25042253 | http://purl.org/dc/terms/identifier | "doi:10.1016/j.bmcl.2014.07.007"xsd:string |
| http://purl.uniprot.org/citations/25042253 | http://purl.uniprot.org/core/author | "Edman K."xsd:string |
| http://purl.uniprot.org/citations/25042253 | http://purl.uniprot.org/core/author | "Giordanetto F."xsd:string |
| http://purl.uniprot.org/citations/25042253 | http://purl.uniprot.org/core/author | "Lindberg J."xsd:string |
| http://purl.uniprot.org/citations/25042253 | http://purl.uniprot.org/core/author | "Karlsson O."xsd:string |
| http://purl.uniprot.org/citations/25042253 | http://purl.uniprot.org/core/author | "Inghardt T."xsd:string |
| http://purl.uniprot.org/citations/25042253 | http://purl.uniprot.org/core/author | "Berglund S."xsd:string |
| http://purl.uniprot.org/citations/25042253 | http://purl.uniprot.org/core/author | "Nylander S."xsd:string |
| http://purl.uniprot.org/citations/25042253 | http://purl.uniprot.org/core/author | "Barlaam B."xsd:string |
| http://purl.uniprot.org/citations/25042253 | http://purl.uniprot.org/core/date | "2014"xsd:gYear |
| http://purl.uniprot.org/citations/25042253 | http://purl.uniprot.org/core/name | "Bioorg Med Chem Lett"xsd:string |
| http://purl.uniprot.org/citations/25042253 | http://purl.uniprot.org/core/pages | "3936-3943"xsd:string |
| http://purl.uniprot.org/citations/25042253 | http://purl.uniprot.org/core/title | "Discovery of 9-(1-phenoxyethyl)-2-morpholino-4-oxo-pyrido[1,2-a]pyrimidine-7-carboxamides as oral PI3Kbeta inhibitors, useful as antiplatelet agents."xsd:string |
| http://purl.uniprot.org/citations/25042253 | http://purl.uniprot.org/core/volume | "24"xsd:string |
| http://purl.uniprot.org/citations/25042253 | http://www.w3.org/2004/02/skos/core#exactMatch | http://purl.uniprot.org/pubmed/25042253 |
| http://purl.uniprot.org/citations/25042253 | http://xmlns.com/foaf/0.1/primaryTopicOf | https://pubmed.ncbi.nlm.nih.gov/25042253 |
| http://purl.uniprot.org/uniprot/#_P48736-mappedCitation-25042253 | http://www.w3.org/1999/02/22-rdf-syntax-ns#object | http://purl.uniprot.org/citations/25042253 |
| http://purl.uniprot.org/uniprot/P48736 | http://purl.uniprot.org/core/mappedCitation | http://purl.uniprot.org/citations/25042253 |